Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP
Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription of IL10 mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioMed Central
2016-12-01
|
| Series: | Genomics & Informatics |
| Subjects: | |
| Online Access: | http://genominfo.org/upload/pdf/gni-14-205.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832573285506744320 |
|---|---|
| author | Min Kyeong Kim Kyong-Ah Yoon Eun Young Park Jungnam Joo Eun Young Lee Hyeon-Seok Eom Sun-Young Kong |
| author_facet | Min Kyeong Kim Kyong-Ah Yoon Eun Young Park Jungnam Joo Eun Young Lee Hyeon-Seok Eom Sun-Young Kong |
| author_sort | Min Kyeong Kim |
| collection | DOAJ |
| description | Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription of IL10 mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the promoter and intron regions, including rs1800896, rs1800871, and rs1800872. However, the impact of polymorphisms of the IL10 gene on NHL prognosis has not been fully elucidated. Here, we investigated the association between IL10 polymorphisms and NHL prognosis. This study involved 112 NHL patients treated at the National Cancer Center, Korea. The median age was 57 years, and 70 patients (62.5%) were men. Clinical characteristics, including age, performance status, stage, and extra-nodal involvement, as well as cell lineage and International Prognostic Index (IPI), were evaluated. A total of four polymorphisms in IL10 with heterozygous alleles were analyzed for hazard ratios of overall survival (OS) and progression-free survival (PFS) using Cox proportional hazards regression analysis. Diffuse large B-cell lymphoma was the most common histologic type (n = 83), followed by T-cell lymphoma (n = 18), mantle cell lymphoma (n = 6), and others (n = 5). Cell lineage, IPI, and extra-nodal involvement were predictors of prognosis. In the additive genetic model results for each IL10 polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These findings suggest that IL10 polymorphisms might be prognostic indicators for patients with B-cell NHL treated with R-CHOP. |
| format | Article |
| id | doaj-art-4e240780c4f3421797507f026fda349e |
| institution | Kabale University |
| issn | 1598-866X 2234-0742 |
| language | English |
| publishDate | 2016-12-01 |
| publisher | BioMed Central |
| record_format | Article |
| series | Genomics & Informatics |
| spelling | doaj-art-4e240780c4f3421797507f026fda349e2025-02-02T04:56:04ZengBioMed CentralGenomics & Informatics1598-866X2234-07422016-12-0114420521010.5808/GI.2016.14.4.205189Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOPMin Kyeong Kim0Kyong-Ah Yoon1Eun Young Park2Jungnam Joo3Eun Young Lee4Hyeon-Seok Eom5Sun-Young Kong6Department of System Cancer Science, Graduate School of Cancer Science and Policy, Goyang 10408, Korea.Center for Breast Cancer, National Cancer Center, Goyang 10408, Korea.Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, Goyang 10408, Korea.Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, Goyang 10408, Korea.Center for Hematologic Malignancy, National Cancer Center, Goyang 10408, Korea.Center for Hematologic Malignancy, National Cancer Center, Goyang 10408, Korea.Department of System Cancer Science, Graduate School of Cancer Science and Policy, Goyang 10408, Korea.Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription of IL10 mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the promoter and intron regions, including rs1800896, rs1800871, and rs1800872. However, the impact of polymorphisms of the IL10 gene on NHL prognosis has not been fully elucidated. Here, we investigated the association between IL10 polymorphisms and NHL prognosis. This study involved 112 NHL patients treated at the National Cancer Center, Korea. The median age was 57 years, and 70 patients (62.5%) were men. Clinical characteristics, including age, performance status, stage, and extra-nodal involvement, as well as cell lineage and International Prognostic Index (IPI), were evaluated. A total of four polymorphisms in IL10 with heterozygous alleles were analyzed for hazard ratios of overall survival (OS) and progression-free survival (PFS) using Cox proportional hazards regression analysis. Diffuse large B-cell lymphoma was the most common histologic type (n = 83), followed by T-cell lymphoma (n = 18), mantle cell lymphoma (n = 6), and others (n = 5). Cell lineage, IPI, and extra-nodal involvement were predictors of prognosis. In the additive genetic model results for each IL10 polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These findings suggest that IL10 polymorphisms might be prognostic indicators for patients with B-cell NHL treated with R-CHOP.http://genominfo.org/upload/pdf/gni-14-205.pdfinterleukin-10non-Hodgkin lymphomaprognosissingle nucleotide polymorphism |
| spellingShingle | Min Kyeong Kim Kyong-Ah Yoon Eun Young Park Jungnam Joo Eun Young Lee Hyeon-Seok Eom Sun-Young Kong Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP Genomics & Informatics interleukin-10 non-Hodgkin lymphoma prognosis single nucleotide polymorphism |
| title | Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP |
| title_full | Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP |
| title_fullStr | Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP |
| title_full_unstemmed | Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP |
| title_short | Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP |
| title_sort | interleukin 10 polymorphisms in association with prognosis in patients with b cell lymphoma treated by r chop |
| topic | interleukin-10 non-Hodgkin lymphoma prognosis single nucleotide polymorphism |
| url | http://genominfo.org/upload/pdf/gni-14-205.pdf |
| work_keys_str_mv | AT minkyeongkim interleukin10polymorphismsinassociationwithprognosisinpatientswithbcelllymphomatreatedbyrchop AT kyongahyoon interleukin10polymorphismsinassociationwithprognosisinpatientswithbcelllymphomatreatedbyrchop AT eunyoungpark interleukin10polymorphismsinassociationwithprognosisinpatientswithbcelllymphomatreatedbyrchop AT jungnamjoo interleukin10polymorphismsinassociationwithprognosisinpatientswithbcelllymphomatreatedbyrchop AT eunyounglee interleukin10polymorphismsinassociationwithprognosisinpatientswithbcelllymphomatreatedbyrchop AT hyeonseokeom interleukin10polymorphismsinassociationwithprognosisinpatientswithbcelllymphomatreatedbyrchop AT sunyoungkong interleukin10polymorphismsinassociationwithprognosisinpatientswithbcelllymphomatreatedbyrchop |